Your session is about to expire
← Back to Search
Tyrosine Kinase Inhibitor
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Phase 1 & 2
Waitlist Available
Research Sponsored by Turning Point Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening to end of treatment approximately 10 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called repotrectinib, used together with other cancer treatments. It targets patients whose cancers have a specific genetic mutation called KRAS, which makes their cancer harder to treat. The drug works by blocking signals that help cancer cells grow and spread. Repotrectinib is a new drug being tested for its effectiveness in treating cancers with KRAS mutations, which are known to be challenging to treat.
Eligible Conditions
- KRAS Mutation-Related Tumors
- Metastatic Tumor
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from screening to end of treatment approximately 10 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening to end of treatment approximately 10 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With Dose Limiting Toxicities
Secondary study objectives
AUC 0-24 of Repotrecitinib
AUC 0-24 of Trametinib
Cmax of Repotrectinib
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: TPX-0005 + TrametinibExperimental Treatment2 Interventions
TPX-0005 + Trametinib Dose Escalation and Dose Expansion
Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trametinib
2014
Completed Phase 2
~1630
Find a Location
Who is running the clinical trial?
Turning Point Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
783 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,582 Previous Clinical Trials
3,388,592 Total Patients Enrolled
8 Trials studying Tumors
422 Patients Enrolled for Tumors
Turning Point Therapeutics, MDStudy DirectorTurning Point Theraperutics
3 Previous Clinical Trials
127 Total Patients Enrolled
Turning Point TherapeuticsStudy DirectorTurning Point Theraperutics